Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
9.13B
Market cap9.13B
Price-Earnings ratio
28.15
Price-Earnings ratio28.15
Dividend yield
Dividend yield
Average volume
2.12M
Average volume2.12M
High today
$78.50
High today$78.50
Low today
$75.71
Low today$75.71
Open price
$78.49
Open price$78.49
Volume
1.61M
Volume1.61M
52 Week high
$82.22
52 Week high$82.22
52 Week low
$52.72
52 Week low$52.72

Stock Snapshot

With a market cap of 9.13B, Halozyme Therapeutics(HALO) trades at $77.56. The stock has a price-to-earnings ratio of 28.15.

As of 2026-07-02, Halozyme Therapeutics(HALO) stock has fluctuated between $75.71 and $78.50. The current price stands at $77.56, placing the stock +2.4% above today's low and -1.2% off the high.

The Halozyme Therapeutics(HALO)'s current trading volume is 1.61M, compared to an average daily volume of 2.12M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $52.72 at its lowest and $82.22 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $52.72 at its lowest and $82.22 at its peak.

HALO News

Simply Wall St 11h
Is Halozyme Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative?

Halozyme Therapeutics, Inc. has appointed David Ramsay as President Drug Delivery, effective June 30, 2026, giving him an enterprise-wide mandate to drive the c...

Is Halozyme Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative?
Nasdaq 7d
ABSCI CORP Soars 36.0%: Is Further Upside Left in the Stock?

Absci Corporation (ABSI) shares soared 36% in the last trading session to close at $10.08. The move was backed by solid volume with far more shares changing han...

ABSCI CORP Soars 36.0%: Is Further Upside Left in the Stock?

Analyst ratings

64%

of 11 ratings
Buy
63.6%
Hold
27.3%
Sell
9.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.